Acesso livre
Acesso livre

Destaques

Nova pesquisa mostra que o excesso de diagnósticos (overdiagnosis) de câncer de mama não é tão comum como se pensava.

8 Mar, 2022 | 17:42h

Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

How often is breast cancer overdiagnosed? New research finds true cases far outweigh false alarms – STAT

Breast cancer overdiagnosis may not happen as frequently as previously thought – ACP Internist

Série Lancet | Envelhecimento com HIV.

8 Mar, 2022 | 17:38h

Página principal: Ageing with HIV

Editoriais:

Ageing with HIV

Time to tackle late diagnosis

Séries:

Delayed presentation of HIV among older individuals: a growing problem

How health systems can adapt to a population ageing with HIV and comorbid disease

Biological ageing with HIV infection: evaluating the geroscience hypothesis

Intersectionality of stigmas and health-related quality of life in people ageing with HIV in China, Europe, and Latin America

Estudo randomizado | Eficácia e segurança de mudar para um regime com 2 medicamentos (dolutegravir/lamivudina) vs. continuar com um regime de 3 a 4 medicamentos visando à manutenção da supressão virológica em adultos portadores de HIV-1.

8 Mar, 2022 | 17:36h

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial – Clinical Infectious Diseases

[Preprint] Estudo RECOVERY mostra que baricitinibe reduz mortes em pacientes internados com COVID-19.

8 Mar, 2022 | 16:22h

Comunicado de imprensa: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Estudo original: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Comentários:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

Conteúdos relacionados:

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

 

Comentário do autor no Twitter (fio – clique para saber mais)

 

Análise sistemática | Variação na taxa de infecção-fatalidade da COVID-19 por idade, tempo e geografia durante a era pré-vacina.

8 Mar, 2022 | 16:19h

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis – The Lancet

Comentário convidado: Understanding of COVID-19 from infection–fatality ratio – The Lancet

Quantificação dos efeitos da pandemia de COVID-19 sobre equidade de gênero nos indicadores de saúde, sociais e econômicos.

8 Mar, 2022 | 16:18h

Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021 – The Lancet

Comentários:

Gender equality and COVID-19: act now before it is too late – The Lancet

Social and economic effects of the COVID-19 pandemic threaten to reverse progress towards gender equality: study – The Lancet

 

Comentário no Twitter (fio – clique para saber mais)

 

M-A | Eficácia das vacinas contra Covid-19 em pacientes imunocomprometidos.

8 Mar, 2022 | 16:16h

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

Comunicado de imprensa: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Conteúdos relacionados: Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review.

 

Comentário no Twitter

 

Diretriz atualizada da OMS recomenda condicionalmente o molnupiravir para pacientes com Covid-19 não grave sob alto risco de internação.

8 Mar, 2022 | 16:14h

Comunicado de imprensa BMJ: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

Comunicado de imprensa OMS: WHO updates its treatment guidelines to include molnupiravir

Ver diretriz atualizada: A living WHO guideline on drugs for covid-19 – BMJ

Conteúdos relacionados:

Editorial (recém-publicado): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Ponto de vista | Compreensão e comunicação da incerteza na obtenção da excelência em diagnósticos.

8 Mar, 2022 | 16:11h

Understanding and Communicating Uncertainty in Achieving Diagnostic Excellence – JAMA (gratuito por tempo limitado)

Estudo de coorte | Associação entre tempo de exposição a telas em crianças de 1 ano de idade e transtorno do espectro autista aos 3 anos de idade.

8 Mar, 2022 | 16:09h

Association Between Screen Time Exposure in Children at 1 Year of Age and Autism Spectrum Disorder at 3 Years of Age: The Japan Environment and Children’s Study – JAMA Pediatrics

Comentário: Screen Time Linked to Autism Spectrum Disorder in Boys – HealthDay

Conteúdos relacionados:

M-A: Global prevalence of meeting screen time guidelines among children 5 years and younger.

Media and Young Minds – American Academy of Pediatrics

Guidelines on Screen Time and Digital Wellness in Infants, Children and Adolescents – “children below 2 years age should not be exposed to any type of screen, whereas exposure should be limited to a maximum of one hour of supervised screen time per day for children 24-59 months age, and less than two hours per day for children 5-10 years age”.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.